Safety and Feasibility of Harvesting Cells for Adoptive Immunotherapy from Patients with Asymptomatic HIV Infection

Trickett, Annette; Dwyer, John M.; Tedla, Nicodemus; Lam-Po-Tang, R

doi:10.1097/00042560-199608150-00014

Cited by 5 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both absolute and percentage of CD8 + cell counts returned to pre-leukapheresis values on day 7. These results are in accordance with those reported previously by other investigators [7,8].…”

Section: Discussionsupporting

confidence: 94%

“…Using an ultrasensitive PCR assay to quantify HIV-1 RNA, we did not observe any increase in viral load in either treated or untreated participants. These results extend those previously reported where P24 antigen was used to monitor viral burden [7,8]. Moreover, in three subjects leukapheresis induces a decrease in viral load shortly after the end of the collection.…”

Section: Discussionsupporting

confidence: 90%

“…Limited information has been re-ported on the impact of leukapheresis on immunological and virological parameters in HIV-1 infected subjects without prior conditioning with growth factors. Previous studies on leukapheresis in HIV-1 infected subjects have shown that this procedure looks safe without significant changes in CD4 + cell counts or viral load [7,8]. However, these studies did not include untreated HIV-1 infected subjects and viral burden was monitored using serum P24 antigen, which is known to be a less sensitive marker than HIV-1 RNA quantitative polymerase chain reaction (PCR) assay.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Changes in immunological and virological parameters in HIV‐1 infected subjects following leukapheresis

Boulassel¹,

Spurll²,

Rouleau³

et al. 2003

J of Clinical Apheresis

View full text Add to dashboard Cite

In order to assess immune responses during HIV-1 therapeutic immunization, a large number of blood mononuclear cells (PBMC) are needed. Clinical tolerance and safety, as well as changes in immunological and virological parameters, were assessed, following leukapheresis in HIV-1 infected subjects with CD4(+) cell count >200 x 10(6)/l. PBMC were collected using a Fenwal CS3000 cell separator in 29 subjects with mean CD4(+) cell counts of 503 x 10(6)/l (range 172-1,119) and viral load of 2.5 log(10) copies/ml (range <1.7-5.4). Twenty-four (83%) subjects were on antiretroviral therapy while 5 (17%) were untreated. The blood volume processed was 7 L over a period of 3 hours. A mean value (+/- standard error) of 82 +/- 26 x 10(9)/l lymphocytes was collected by a single apheresis in a mean volume of 200 +/- 1.8 ml, containing 9.0 +/- 1.3 x 10(9)/l CD4(+) and 10.2 +/- 1.3 x 10(9)/l CD8(+) cells. The leukapheresis procedures were well tolerated and no immediate or delayed side effects were observed within 90 days of follow-up. No changes from blood pre-leukapheresis values were detected for white blood cells, lymphocytes, monocytes, CD8(+), CD34(+), naive and memory CD4(+) cell counts immediately after, 1 h, 7 days, or within 90 days after leukapheresis. However, absolute CD4(+) cell counts and percentage significantly increased from pre-leukapheresis values after 1 h (530 +/- 43 vs. 700 +/- 75 cell x 10(6)/l; 32.6 +/- 1.6 vs. 36.9 +/- 1.9%; P < 0.001 for both paired t-tests) before returning to pre-leukapheresis levels on day 7. No significant changes in viral load from pre-leukapheresis levels in treated or untreated subjects were detected at any time points. We conclude that leukapheresis in HIV-1 infected subjects with CD4(+) cell counts >200 x 10(6)/l is safe and induces a transient increase in the absolute and percentage of CD4(+) cell count without enhancing viral replication.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changes in immunological and virological parameters in HIV‐1 infected subjects following leukapheresis

Boulassel¹,

Spurll²,

Rouleau³

et al. 2003

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

“…Leukapheresis packs were collected between 1992 and 1994, and cells were cryopreserved as part of a study of adoptive immunotherapy. 44 However, these samples preceded routine plasma viral load testing, and no results are available for HIV RNA copy numbers for the times of collection.…”

Section: Patientsmentioning

confidence: 99%

The Majority of HIV Type 1 DNA in Circulating CD4⁺T Lymphocytes Is Present in Non-Gut-Homing Resting Memory CD4⁺T Cells

McBride

Xu²,

Bailey³

et al. 2013

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Memory CD4+ T lymphocytes in peripheral blood that express integrins a4ß7 preferentially recirculate through gut-associated lymphoid tissue (GALT), a proposed site of significant HIV-1 replication. Tregs and activated CD4 + T cells in GALT could also be particularly susceptible to infection. We therefore hypothesized that infection of these subsets of memory CD4+ T cells may contribute disproportionately to the HIV-1 reservoir. A cross-sectional study of CD4 + T cell subsets of memory CD45RO + cells in peripheral blood mononuclear cells (PBMCs) was conducted using leukapheresis from eight subjects with untreated chronic HIV-1 infection. Realtime polymerase chain reaction (PCR) was used to quantify total and integrated HIV-1 DNA levels from memory CD4 + T cells sorted into integrin b7 + vs. b7 -, CD25 + CD127 low Treg vs. CD127 high , and activated CD38 + vs. CD38 -. More than 80% of total HIV-1 DNA was found to reside in the integrin b7-negative nongut-homing subset of CD45RO + memory CD4 + T cells. Less than 10% was found in highly purified Tregs or CD38+ activated memory cells. Similarly, integrated HIV-1 DNA copies were found to be more abundant in resting non-gut-homing memory CD4 + T cells (76%) than in their activated counterparts (23%). Our investigations showed that the majority of both total and integrated HIV-1 DNA was found within non-gut-homing resting CD4 + T cells.

show abstract

Ex vivo expansion of functional T lymphocytes from HIV-infected individuals

Trickett

Kwan

Cameron

et al. 2002

Journal of Immunological Methods

View full text Add to dashboard Cite

Safety and Feasibility of Harvesting Cells for Adoptive Immunotherapy from Patients with Asymptomatic HIV Infection

Cited by 5 publications

References 10 publications

Changes in immunological and virological parameters in HIV‐1 infected subjects following leukapheresis

Changes in immunological and virological parameters in HIV‐1 infected subjects following leukapheresis

The Majority of HIV Type 1 DNA in Circulating CD4⁺T Lymphocytes Is Present in Non-Gut-Homing Resting Memory CD4⁺T Cells

Ex vivo expansion of functional T lymphocytes from HIV-infected individuals

Contact Info

Product

Resources

About

Safety and Feasibility of Harvesting Cells for Adoptive Immunotherapy from Patients with Asymptomatic HIV Infection

Cited by 5 publications

References 10 publications

Changes in immunological and virological parameters in HIV‐1 infected subjects following leukapheresis

Changes in immunological and virological parameters in HIV‐1 infected subjects following leukapheresis

The Majority of HIV Type 1 DNA in Circulating CD4+T Lymphocytes Is Present in Non-Gut-Homing Resting Memory CD4+T Cells

Ex vivo expansion of functional T lymphocytes from HIV-infected individuals

Contact Info

Product

Resources

About

The Majority of HIV Type 1 DNA in Circulating CD4⁺T Lymphocytes Is Present in Non-Gut-Homing Resting Memory CD4⁺T Cells